Lunit

328130.KQ

40.99 USD

-0.15

-0.36%

Overview

Last close

40.99 usd

Market cap

1.18B usd

52 week high

76.72 usd

52 week low

23.39 usd

Target price

39.83 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

31.0155

Price/Book Value

7.3851

Enterprise Value

1.17B usd

EV/Revenue

43.2104

EV/EBITDA

-45.3273

Key financials

Revenue TTM

17.88M usd

Gross Profit TTM

4.56M usd

EBITDA TTM

-39.57M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

326.02M usd

Net debt

8.10M usd

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.